TipsForTraders

One Must-Buy High-Yield Healthcare Stock and One to Steer Clear Of

Hannah Perry | October 22, 2024

One Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and One to Avoid The healthcare sector isn’t typically the go-to choice for income investors looking for high dividend yields. In fact, when ranked among the 11 sectors of the S&P 500, healthcare comes in eighth place based on average dividend yield. Nonetheless, there are still…

Discover Top 5 Biotech Stocks Set to Outperform the Market in 2023

Hannah Perry | October 21, 2024

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks In mid-October, biotech stocks marked a significant recovery as they regained their 50-day moving average, propelled by encouraging results from Wave Life Sciences (WVE) in RNA editing. While the resurgence offers a glimmer of hope, it still falls short of the buoyant levels experienced…

Weight-Loss Medications Show Promise in Reducing Opioid and Alcohol Abuse Rates

Hannah Perry | October 18, 2024

Weight-Loss Medications Present New Hope Against Substance Abuse Recent findings suggest that weight-loss medications such as Ozempic and Wegovy may not only assist in weight management and diabetes control but could also play a significant role in reducing opioid and alcohol abuse. A noteworthy study published in the scientific journal Addiction indicates that these medications…

Abbott Laboratories Exceeds Q3 Expectations and Raises Full-Year Earnings Forecast

Hannah Perry | October 17, 2024

Abbott Laboratories Surpasses Q3 Expectations and Optimizes Full-Year Forecast Abbott Laboratories, a key player in the healthcare products sector, reported robust third-quarter results on Wednesday, exceeding market expectations in both sales and earnings. This positive performance was largely attributed to the company’s thriving medical-devices division. The Abbott Park, Illinois-based company has also raised its earnings…

Two Medical Stocks to Watch: Potential Earnings Surprises from Moderna and Tactile Systems Technology

Hannah Perry | October 16, 2024

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Earnings reports hold significant weight in the world of finance, and one number stands out above the rest: the earnings per share (EPS). This singular figure has the power to sway investors’ perceptions and trigger stock price movements. While Wall Street…

UnitedHealth’s Third-Quarter Results: Key Insights on Medical Costs and Healthcare Utilization Trends

Hannah Perry | October 15, 2024

All Eyes on Medical Costs as UnitedHealth Reports Third-Quarter Results Investor Concerns Surrounding Healthcare Utilization When UnitedHealth Group, a prominent healthcare services firm, releases its third-quarter financial results early Tuesday, the key focus for investors will be the trend in medical services utilization among seniors. The health sector has been in turmoil following UnitedHealth’s fourth-quarter…

FDA’s Major Shift: Compounded Versions of Eli Lilly’s Weight Loss Drug Get a Second Chance

Hannah Perry | October 14, 2024

US FDA to Reconsider Decision Barring Compounded Versions of Lilly’s Weight Loss Drug The U.S. Food and Drug Administration (FDA) has made a significant decision to reconsider its previous ruling that restricted drug compounders from selling their own formulations of Eli Lilly’s (LLY.N) popular weight loss and diabetes drugs. This reconsideration comes in light of…

Upstream Bio Leads Surge of Biotech IPOs as Healthcare Sector Gains Momentum

Hannah Perry | October 11, 2024

Upstream Bio and Two Other Biotech Startups Price Successful IPOs Amid Rising Healthcare Listings On Thursday, three U.S. healthcare startups successfully priced their initial public offerings (IPOs), showcasing a significant uptick in the sector’s activity. Leading the pack was Upstream Bio (UPB.O), raising an impressive $255 million at a valuation of approximately $830 million. This…

Viking Therapeutics Achieves Breakthrough Results in X-ALD Treatment Trial for VK0214

Hannah Perry | October 10, 2024

Viking Therapeutics Reports Positive Data in Trial for X-ALD Treatment Promising Results for VK0214 Viking Therapeutics Inc., a San Diego-based biopharmaceutical company, announced on Wednesday that it has achieved positive results from an early-stage trial for VK0214, a treatment aimed at the rare metabolic disorder X-linked adrenoleukodystrophy (X-ALD). X-ALD is a severe condition that usually…

Pfizer Stock Soars as Starboard Value Invests $1 Billion: What it Means for Bondholders and Future Growth

Hannah Perry | October 9, 2024

Pfizer Bondholders Respond Positively to Starboard Value’s $1 Billion Investment On Monday, Pfizer Inc. (PFE) saw its stock rise following news that Starboard Value, a well-known activist investor, has made a significant $1 billion investment in the pharmaceutical giant. The announcement has not only invigorated the stock market response but also prompted bondholders to react…

DISCLAIMERS – THIS IS A PAID ADVERTISEMENT.

TipsForTraders.com

This is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public and private companies. By reading this email, our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing.

This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.

For a full disclaimer & disclosure please click here.

This communication is a paid advertisement and is not a recommendation to buy or sell securities. IR PUB Network, and its owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled companies or a third party to disseminate this communication. IThis compensation is a major conflict with our ability to be unbiased, more specifically: This communication is for entertainment purposes only. Never invest purely based on our communication.

Gains mentioned in this article, in our newsletter and on our website may be based on end-of-day or intraday data. Therefore, this communication should be viewed as a commercial advertisement only. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, IR PUB Network often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, and approved by the company that is featured herein, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s).

You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. We have not thoroughly investigated the background of any of the companies we profile. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.

NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.

ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our featured profiles on Companies. Gains mentioned in our website / media webpage(s) may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this message and the product materials are for illustrative purposes only and not to be construed as specific advisory recommendations. All ideas and material presented are entirely those of the author and do not necessarily reflect those of the publisher.

Blog